Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

Although schizophrenia presents differently in each individual, symptoms are typically classified into three different categories: positive, negative and cognitive symptoms. “Positive symptoms ...

Explore how LB Pharmaceuticals is revolutionizing the pharma industry with its innovative therapies for neuropsychiatric ...

Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with ...

Brexpiprazole was associated with a greater reduction in schizophrenia symptoms over 6 weeks in ... The primary outcome was change in Positive and Negative Syndrome Scale (PANSS) total score ...